alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
# C_2014303EN.01001401.xml

| 8.9.2014 | EN | Official Journal of the European Union | C 303/14 |
| --- | --- | --- | --- |

8.9.2014

EN

Official Journal of the European Union

C 303/14

---

Appeal brought on 3 June 2014 by Debonair Trading Internacional Lda against the judgment of the General Court (Ninth Chamber) delivered on 3 April 2014 in Case T-356/12: Debonair Trading Internacional Lda v Office for Harmonisation in the Internal Market (Trade Marks and Designs) (OHIM)

a

a

(Case C-270/14 P)

2014/C 303/18

Language of the case: English

Parties

Parties

Appellant: Debonair Trading Internacional Lda (represented by: T. Alkin, Barrister)

Appellant:

a

Other party to the proceedings: Office for Harmonisation in the Internal Market (Trade Marks and Designs)

Other party to the proceedings:

Form of order sought

Form of order sought

The appellant claims that the Court should:

| 1) | Set aside paragraph 2 of the Decision dismissing the action as to the remainder; |
| --- | --- |

1)

Set aside paragraph 2 of the Decision dismissing the action as to the remainder;

| 2) | Remit the case to the General Court for further consideration with direction as to the applicable law; |
| --- | --- |

2)

Remit the case to the General Court for further consideration with direction as to the applicable law;

| 3) | Order the Respondent to pay the costs both of the proceedings before the General Court and those before the Court of Justice. |
| --- | --- |

3)

Order the Respondent to pay the costs both of the proceedings before the General Court and those before the Court of Justice.

Pleas in law and main arguments

Pleas in law and main arguments

The Appellant relies on a single plea in law, namely infringement of Article 8(1)(b) CTMR (1). In summary, it contends that the General Court erred by purporting to limit the conditions in which a likelihood of confusion may arise between a ‘family’ of trade marks and a later trade mark. Alternatively the Appellant contends that the General Court failed to carry out a global assessment of the likelihood of confusion taking into account all relevant factors.

1

---

(1)  Council Regulation (EC) No 207/2009 of 26 February 2009 on the Community trade mark,

1

OJ L 78, p. 1

---
I 

118TH CONGRESS 

2D SESSION H. R. 7482 

To amend the Public Health Service Act to reauthorize the WISEWOMAN 

program. 

IN THE HOUSE OF REPRESENTATIVES 

FEBRUARY 29, 2024 

Mrs. BEATTY (for herself and Ms. DELAURO) introduced the following bill; 

which was referred to the Committee on Energy and Commerce 

A BILL 

To amend the Public Health Service Act to reauthorize the 

WISEWOMAN program. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘Women’s Heart Health 

5 Expansion Act of 2024’’. 

6 SEC. 2. REAUTHORIZATION OF WISEWOMAN PROGRAM. 

7 Section 1509 of the Public Health Service Act (42 

8 U.S.C. 300n–4a) is amended to read as follows: 


kjohnson on DSK7ZCZBW3PROD with $$_JOB
2 

•HR 7482 IH

1 ‘‘SEC. 1509. SUPPLEMENTAL GRANTS FOR ADDITIONAL 

2 PREVENTIVE HEALTH SERVICES. 

3 ‘‘(a) SCREENING AND REFERRAL PROJECTS.—The 

4 Secretary, acting through the Director of the Centers for 

5 Disease Control and Prevention, may award supplemental 

6 grants to recipients of grants under section 1501 to carry 

7 out projects for the purposes of— 

8 ‘‘(1) providing preventive health services in ad9 dition to the services authorized in such section, in10 cluding— 

11 ‘‘(A) screenings regarding blood pressure 

12 and cholesterol; and 

13 ‘‘(B) health education; 

14 ‘‘(2) providing appropriate referrals for medical 

15 treatment of women receiving services pursuant to 

16 paragraph (1) and ensuring, to the extent prac17 ticable, the provision of appropriate follow-up serv18 ices; and 

19 ‘‘(3) evaluating activities conducted under para20 graphs (1) and (2) through appropriate surveillance 

21 or program-monitoring activities. 

22 ‘‘(b) ELIGIBILITY FOR SERVICES.—Women eligible 

23 for services pursuant to a grant under subsection (a) shall 

24 include— 

25 ‘‘(1) women receiving services pursuant to a 

26 grant made under section 1501; and 


kjohnson on DSK7ZCZBW3PROD with $$_JOB
3 

•HR 7482 IH

1 ‘‘(2) other women who are low-income and meet 

2 such eligibility criteria as the Secretary may specify. 

3 ‘‘(c) AUTHORIZED PROVIDERS.—Services provided 

4 pursuant to a grant under subsection (a) shall be provided 

5 by— 

6 ‘‘(1) an entity screening women for breast and 

7 cervical cancer pursuant to a grant under section 

8 1501; or 

9 ‘‘(2) other entities that the grant recipient may 

10 designate, subject to the approval of such designa11 tion by the Secretary. 

12 ‘‘(d) APPLICABILITY OF PROVISIONS OF GENERAL

13 PROGRAM.—This title applies to a grant under subsection 

14 (a) to the same extent and in the same manner as this 

15 title applies to a grant under section 1501. 

16 ‘‘(e) FUNDING.—To carry out this section, there is 

17 authorized to be appropriated $250,000,000 for the period 

18 of fiscal years 2025 through 2029.’’. 

Æ 


kjohnson on DSK7ZCZBW3PROD with $$_JOB
§ 526.365 Cephapirin sodium. ( a ) *Specifications.* Each single-dose, 10-milliliter syringe contains 200 milligrams (mg) cephapirin sodium activity.
( b ) *Sponsor.* See No. 000010 in § 510.600(c) of this chapter.
( c ) *Related tolerances.* See § 556.115 of this chapter.
( d ) *Conditions of use in lactating cows* — ( 1 ) *Amount.* Infuse the contents of one syringe (200 mg cephapirin activity) into each infected quarter immediately after the quarter has been completely milked out. Do not milk out for 12 hours. Repeat once only in 12 hours.
( 2 ) *Indications for use.* For the treatment of mastitis in lactating cows caused by susceptible strains of *Streptococcus agalactiae* and *Staphylococcus aureus* including strains resistant to penicillin.
( 3 ) *Limitations.* Milk that has been taken from animals during treatment and for 96 hours after the last treatment must not be used for food. Treated animals must not be slaughtered for food until 4 days after the last treatment. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[40 FR 57455, Dec. 10, 1975, as amended at 53 FR 27852, July 25, 1988. Redesignated at 63 FR 8349, Feb. 19, 1998; 65 FR 20733, Apr. 18, 2000; 73 FR 3181, Jan. 17, 2008; 75 FR 10168, Mar. 5, 2010; 86 FR 13186, Mar. 8, 2021; 88 FR 16549, Mar. 20, 2023]
Editorial Note on Part 60
Editorial Note: Nomenclature changes to part 60 appear at 68 FR 24879, May 9, 2003, and at 88 FR 45065, July 14, 2023.

§ 60.30 Filing, format, and content of petitions. ( a ) Any person may file a petition with FDA, no later than 180 days after the publication of a regulatory review period determination under § 60.20, that challenges FDA's determination by alleging that the applicant for patent term restoration did not act with due diligence in seeking FDA approval of the product during the regulatory review period.
( b ) The petition shall be filed in accordance with § 10.20, under the docket number of the Federal Register notice of the agency's regulatory review period determination, and shall be in the format specified in § 10.30. The petition shall contain the information specified in § 10.30 and any additional information required by this subpart. If any provision of § 10.20 or § 10.30 is inconsistent with any provision of this part, FDA will consider the petition in accordance with this part.
( c ) The petition shall claim that the applicant did not act with due diligence during some part of the regulatory review period and shall set forth sufficient facts, including dates if possible, to merit an investigation by FDA of whether the applicant acted with due diligence.
( d ) The petition shall contain a certification that the petitioner has served a true and complete copy of the petition upon the applicant by certified or registered mail (return receipt requested) or by personal delivery.
[53 FR 7305, Mar. 7, 1988, as amended at 67 FR 9585, Mar. 4, 2002]
# C_2015127EN.01000601.xml

| 20.4.2015 | EN | Official Journal of the European Union | C 127/6 |
| --- | --- | --- | --- |

20.4.2015

EN

Official Journal of the European Union

C 127/6

---

Appeal brought on 4 February 2014 by Recaro Holding GmbH, formerly Recaro Beteiligungs-GmbH against the judgment of the General Court (Seventh Chamber) delivered on 21 November 2013 in Case T-524/12: Recaro Holding GmbH v Office for Harmonisation in the Internal Market (Trade Marks and Designs)

(Case C-57/14 P)

(2015/C 127/08)

Language of the case: English

Parties

Parties

Appellant: Recaro Holding GmbH, formerly Recaro Beteiligungs-GmbH (represented by: J. Weiser, Rechtsanwalt)

Appellant:

Other party to the proceedings: Office for Harmonisation in the Internal Market (Trade Marks and Designs)

Other party to the proceedings:

By order of 14 January 2015 the Court of Justice (Seventh Chamber) has dismissed the appeal and ordered Recaro Holding GmbH to bear its own costs.

---
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Agriculture

###### Forest Service

# AGENCY:

Forest Service, USDA.

# ACTION:

Notice of meeting.

# SUMMARY:

Pursuant to the authorities in the Federal Advisory Committee Act (Pub. L. 92-463) and under the Secure Rural Schools and Community Self-Determination Act of 2000, as amended, (Pub. L. 110-343), the Boise, Payette, and Sawtooth National Forests' Southwest Idaho Resource Advisory Committee will conduct a business meeting. The meeting is open to the public.

# DATES:

Thursday, March 18, 2010, beginning at 10:30 a.m.

# ADDRESSES:

Idaho Counties Risk Management Program Building, 3100 South Vista Avenue, Boise, Idaho.

# SUPPLEMENTARY INFORMATION:

Agenda topics will include review and approval of project proposals, and is an open public forum.

# FOR FURTHER INFORMATION CONTACT:

                        Dale Olson, Designated Federal Official, at (208) 347-0322 or e-mail                         *dolson07@fs.fed.us.*

Dated: February 19, 2010.

Suzanne C. Rainfille,

Forest Supervisor, Payette National Forest.

[FR Doc. 2010-3983 Filed 2-26-10; 8:45 am]

BILLING CODE 3410-11-M
Exhibit 32




    Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to
                 Section 906 of the Sarbanes-Oxley Act of 2002


May 16, 2005


Securities and Exchange Commission
450 Fifth Street, N.W.
Washington, D.C. 20549


Re:  Certification Required Under Section 906 of Sarbanes-Oxley Act of 2002

In  connection  with the  accompanying  report on Form 10-Q for the period ended
March 31, 2005,  and filed with the  Securities  and Exchange  Commission on the
date hereof (the  "Report"),  we, Allan D. Keel,  President  and CEO of GulfWest
Energy Inc.  (the  "Company"),  and E. Joseph Grady,  Senior Vice  President and
Chief Financial Officer of the Company hereby certify that:

      1. The report fully  complies  with the  requirements  of Section 13(a) or
15(d) of the Securities Exchange Act of 1934; and

       2. The  information  contained  in the  Report  fairly  presents,  in all
material  respects,  the  financial  condition  and results of operations of the
Company.


GulfWest Energy Inc.


/S/ Allan D. Keel
-------------------------------------
By: Allan D. Keel
President and Chief Executive Officer


/S/ E. Joseph Grady
-------------------------------------
By: E. Joseph Grady
Senior Vice President and Chief Financial Officer
[Federal Register Volume 75, Number 38 (Friday, February 26, 2010)]
[Notices]
[Pages 8918-8919]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2010-4052]


-----------------------------------------------------------------------

DEPARTMENT OF COMMERCE

Foreign-Trade Zones Board

[Order No. 1663]


Approval for Subzone Expansion and Expanded Manufacturing 
Authority; Foreign-Trade Subzone 119B, Uponor, Inc. (Polyethylene 
Tubing); Apple Valley, MN

    Pursuant to its authority under the Foreign-Trade Zones Act of 
June 18, 1934, as amended (19 U.S.C. 81a-81u), the Foreign-Trade 
Zones Board (the Board) adopts the following Order:

    Whereas, the Greater Metropolitan Area Foreign-Trade Zone 
Commission,

[[Page 8919]]

grantee of Foreign-Trade Zone 119 (Minneapolis, Minnesota), has 
submitted a request on behalf of Uponor, Inc. (Uponor), operator of 
Subzone 119B at the Uponor polyethylene tubing manufacturing and 
distribution facilities in Apple Valley, Minnesota, to expand and 
reorganize the subzone and to expand the scope of FTZ manufacturing 
authority to include new production capacity (FTZ Docket 61-2008, filed 
10-28-08);
    Whereas, notice inviting public comment has been given in the 
Federal Register (73 FR 65582, 11-4-08) and the application has been 
processed pursuant to the FTZ Act and the Board's regulations; and,
    Whereas, the Board adopts the findings and recommendations of the 
examiner's report, and finds that the requirements of the FTZ Act and 
Board's regulations are satisfied, and that the proposal is in the 
public interest;
    Now, therefore, the Board hereby orders:
    The application to expand and reorganize the subzone and to expand 
the scope of FTZ manufacturing authority within Subzone 119B, as 
described in the application and Federal Register notice, is approved, 
subject to the FTZ Act and the Board's regulations, including Section 
400.28.

    Signed at Washington, DC, February 5, 2010.
Ronald K. Lorentzen,
Deputy Assistant Secretary for Import Administration, Alternate 
Chairman, Foreign-Trade Zones Board.
Andrew McGilvray,
Executive Secretary.
[FR Doc. 2010-4052 Filed 2-25-10; 8:45 am]
BILLING CODE 3510-DS-P
<TABLE> <S> <C>

<PAGE>
<ARTICLE> 5
<MULTIPLIER> 1,000
       
<S>                             <C>
<PERIOD-TYPE>                   YEAR
<FISCAL-YEAR-END>                          DEC-28-1997
<PERIOD-START>                             DEC-30-1996
<PERIOD-END>                               DEC-28-1997
<CASH>                                          11,415
<SECURITIES>                                         0
<RECEIVABLES>                                   41,287
<ALLOWANCES>                                       500
<INVENTORY>                                    104,117
<CURRENT-ASSETS>                               178,198
<PP&E>                                       1,249,167
<DEPRECIATION>                                 627,891
<TOTAL-ASSETS>                                 880,580
<CURRENT-LIABILITIES>                          135,539
<BONDS>                                        430,878
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                       132,698
<OTHER-SE>                                    (22,091)
<TOTAL-LIABILITY-AND-EQUITY>                   880,580
<SALES>                                        897,492
<TOTAL-REVENUES>                               897,492
<CGS>                                          837,452
<TOTAL-COSTS>                                  837,452
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                   599
<INTEREST-EXPENSE>                              50,321
<INCOME-PRETAX>                               (34,663)
<INCOME-TAX>                                  (12,132)
<INCOME-CONTINUING>                           (22,531)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                  (22,531)
<EPS-PRIMARY>                                        0
<EPS-DILUTED>                                        0
        

</TABLE>
Editorial Note on Part 15
Editorial Note: Nomenclature changes to part 15 appear at 88 FR 45065, July 14, 2023.

§ 15.30 Conduct of a public hearing before the Commissioner. ( a ) The Commissioner or a designee may preside at the hearing, except where a regulation provides that the Commissioner will preside personally. The presiding officer may be accompanied by other FDA employees or other Federal Government employees designated by the Commissioner, who may serve as a panel in conducting the hearing.
( b ) The hearing will be transcribed.
( c ) Persons may use their alloted time in whatever way they wish, consistent with a reasonable and orderly hearing. A person may be accompanied by any number of additional persons, and may present any written information or views for inclusion in the record of the hearing, subject to the requirements of § 15.25. The presiding officer may allot additional time to any person when the officer concludes that it is in the public interest, but may not reduce the time allotted for any person without the consent of the person.
( d ) If a person is not present at the time specified for the presentation, the persons following will appear in order, with adjustments for those appearing at their scheduled time. An attempt will be made to hear any person who is late at the conclusion of the hearing. Other interested persons attending the hearing who did not request an opportunity to make an oral presentation will be given an opportunity to make an oral presentation at the conclusion of the hearing, in the discretion of the presiding officer, to the extent that time permits.
( e ) The presiding officer and any other persons serving on a panel may question any person during or at the conclusion of the presentation. No other person attending the hearing may question a person making a presentation. The presiding officer may, as a matter of discretion, permit questions to be submitted to the presiding officer or panel for response by them or by persons attending the hearing.
( f ) The hearing is informal in nature, and the rules of evidence do not apply. No motions or objections relating to the admissibility of information and views may be made or considered, but other participants may comment upon or rebut all such information and views. No participant may interrupt the presentation of another participant at any hearing for any reason.
( g ) The hearing may end early only if all persons scheduled for a later presentation have already appeared or it is past the time specified in the hearing schedule, under § 15.21(e), by which participants must be present.
( h ) The Commissioner or the presiding officer may, under § 10.19, suspend, modify, or waive any provision of this part.
§ 814.110 New indications for use. ( a ) An applicant seeking a new indication for use of a HUD approved under this subpart H shall obtain a new designation of HUD status in accordance with § 814.102 and shall submit an original HDE in accordance with § 814.104.
( b ) An application for a new indication for use made under § 814.104 may incorporate by reference any information or data previously submitted to the agency under an HDE.
Exhibit 32.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER  Pursuant to 18 U.S.C. Section 1350, as adopted  Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

The undersigned, John P. Wilmers, Chief Executive Officer of Ballantyne of Omaha, Inc. (the "Company"), has executed this certification
in connection with the filing with the Securities and Exchange Commission of the Company's Annual Report on Form 10-K for the year ended December 31, 2008 (the "Report").

The
undersigned hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to his knowledge
that:



IN
WITNESS WHEREOF, the undersigned has executed this certification as of the 25th day of June 2009.

/s/ JOHN P. WILMERS John P. Wilmers
Chief Executive Officer


A
signed original of this written statement required by Section 906 has been provided to Ballantyne of Omaha, Inc. and will be retained by Ballantyne of Omaha, Inc. and furnished to the
Securities and Exchange Commission or its staff upon request.

---



QuickLinks
§ 803.21 Where can I find the reporting codes for adverse events that I use with medical device reports? ( a ) The MedWatch Medical Device Reporting Code Instruction Manual contains adverse event codes for use with Form FDA 3500A. You may obtain the coding manual from FDA's website at: *https://www.fda.gov/medical-devices/mandatory-reporting-requirements-manufacturers-importers-and-device-user-facilities/mdr-adverse-event-codes .*
( b ) We may sometimes use additional coding of information on the reporting forms or modify the existing codes. If we do make modifications, we will ensure that we make the new coding information available to all reporters.
[79 FR 8846, Feb. 14, 2014, as amended at 85 FR 18441, Apr. 2, 2020]
§ 582.1973 Beeswax. ( a ) *Product.* Beeswax (yellow wax).
( b ) *Conditions of use.* This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.